Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
<!-- Name:DistributionId Value:8824304 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4577 -->…
Browsing Tag
ulcerative colitis
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor WALTHAM, Mass., Oct. 10, 2022 (GLOBE…
Colorectal Procedure Market to Garner $29.55Bn, Globally, by 2028 Growing at 13.1% CAGR | Exclusive…
New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Colorectal Procedure Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Surgery Type , End User and Indication,”…
First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced…
BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for …
Vedolizumab for Ulcerative Colitis Works Best When Given Early
More ulcerative colitis patients responded to vedolizumab (Entyvio) when they started it soon after their diagnosis rather than after other therapies, insurance claims…
Crohn’s Disease Scores With Interchangeable Humira Biosimilar
On October 18, 2021, MedPage Today reported on the approval of Cyltezo, the first interchangeable biosimilar approval for adalimumab (Humira),…
First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical…
BOCA RATON, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted,…
Statins may be Effective Treatment for Ulcerative Colitis Patients: Study
"About 30% of ulcerative colitis patients eventually have to undergo a colectomy as a last resort. It's a drastic measure; you're removing part of your body," said Khatri. "So we thought, 'Can we use available data to see whether…
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio…
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic…
FDA Slaps Restrictions on JAK Inhibitors Over Serious Safety Risks
The FDA has finished its review of a large postmarketing safety study of tofacitinib (Xeljanz, Xeljanz XR), and its conclusions do not bode well…